Fulcrum Therapeutics Inc (FULC)
7.66
-0.04
(-0.52%)
USD |
NASDAQ |
May 21, 16:00
7.66
0.00 (0.00%)
After-Hours: 18:22
Fulcrum Therapeutics Enterprise Value: 265.27M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 265.27M |
| May 17, 2024 | 255.95M |
| May 16, 2024 | 271.17M |
| May 15, 2024 | 299.45M |
| May 14, 2024 | 278.32M |
| May 13, 2024 | 243.52M |
| May 10, 2024 | 250.97M |
| May 09, 2024 | 252.84M |
| May 08, 2024 | 258.43M |
| May 07, 2024 | 255.32M |
| May 06, 2024 | 268.38M |
| May 03, 2024 | 268.38M |
| May 02, 2024 | 262.16M |
| May 01, 2024 | 242.27M |
| April 30, 2024 | 229.84M |
| April 29, 2024 | 226.73M |
| April 26, 2024 | 230.46M |
| April 25, 2024 | 229.84M |
| April 24, 2024 | 239.16M |
| April 23, 2024 | 249.11M |
| April 22, 2024 | 237.30M |
| April 19, 2024 | 211.82M |
| April 18, 2024 | 225.49M |
| April 17, 2024 | 230.99M |
| April 16, 2024 | 247.15M |
| Date | Value |
|---|---|
| April 15, 2024 | 244.04M |
| April 12, 2024 | 252.74M |
| April 11, 2024 | 272.01M |
| April 10, 2024 | 278.22M |
| April 09, 2024 | 311.78M |
| April 08, 2024 | 311.78M |
| April 05, 2024 | 316.13M |
| April 04, 2024 | 346.58M |
| April 03, 2024 | 354.03M |
| April 02, 2024 | 350.30M |
| April 01, 2024 | 365.22M |
| March 28, 2024 | 348.45M |
| March 27, 2024 | 349.69M |
| March 26, 2024 | 329.25M |
| March 25, 2024 | 347.83M |
| March 22, 2024 | 362.69M |
| March 21, 2024 | 370.12M |
| March 20, 2024 | 367.03M |
| March 19, 2024 | 389.32M |
| March 18, 2024 | 390.56M |
| March 15, 2024 | 467.36M |
| March 14, 2024 | 456.21M |
| March 13, 2024 | 467.36M |
| March 12, 2024 | 439.49M |
| March 11, 2024 | 462.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-158.26M
Minimum
Apr 12 2023
1.122B
Maximum
Sep 20 2021
234.05M
Average
208.77M
Median
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 133.96B |
| Moderna Inc | 45.52B |
| Pfizer Inc | 218.72B |
| NovaBay Pharmaceuticals Inc | 7.267M |
| Palatin Technologies Inc | 22.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.87M |
| Total Expenses (Quarterly) | 29.83M |
| EPS Diluted (Quarterly) | -0.43 |
| Earnings Yield | -20.89% |
| Normalized Earnings Yield | -20.63 |